Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

Artizan announces corporate progress and financing

Artizan Biosciences has announced corporate and financial updates: Artizan has completed its Series A funding, bringing the total raised to date to $12 million. Paul...

| By Bill Kelly

UConn looks at bioinformatics and bone health

A team of University of Connecticut researchers has received a $2.8 million grant from the National Institutes of Health for a five-year project studying how...

| By Bill Kelly

Help for Business in 2019 Connecticut Legislation

From the Rome Smith & Lutz team: The Connecticut General Assembly adjourned sine die the 2019 regular legislative session.  Governor Lamont will address the joint...

| By Kelley Gipson

Hamden biotech Vanessa advances in Turkey

Vanessa Research has been granted regulatory approval by the Turkish Ministry of Health to conduct a Phase II Clinical Trial for Shylicine®, an investigational oral...

| By Bill Kelly

SpringWorks gets fast track re neurofibromatosis

SpringWorks Therapeutics reports that the FDA has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment...

| By Bill Kelly

Connecticut companies exhibit at BIO convention

Four New Haven-area companies exhibiting at Bio 2019, one the world’s largest forums for the biotech sector. More than 16,000 attendees are taking part in...

| By Bill Kelly

Intensity presents positive Phase 1/2 results

Intensity Therapeutics reports positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American...

| By Kelley Gipson

Bayer and Arvinas to collaborate

Bayer and Arvinas report an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and...